P I Industries Ltd

- The company currently has a strong cash position and is not in a hurry to deploy available cash. - They are actively evaluating several inorganic opportunities domestically and internationally, including technology areas outside India. - There is no specific mention of planned fundraising through debt or equity in the near term. - The company prefers to sit on cash and wait for the right set of opportunities rather than raising funds immediately.

- The company is actively investing in its Pharma CRDMO platform, focusing on capability-building, people, processes, and planned upgrades/additions to assets to support strategic growth. - In electronic chemicals, there are two dedicated plants: one near commissioning and another multi-product plant, indicating ongoing capex in this segment. - Biologicals business is currently in the investment phase, including market and product development across the US, Brazil, Europe, Mexico, and India, along with commissioning a new biological research center in Hyderabad. - The company is evaluating several inorganic opportunities domestically and internationally but is cautious due to market uncertainties and is willing to hold cash while seeking the right opportunities. - No specific quantitative capex figures were disclosed for these investments.

- Biologicals business is a global long-term play currently in the investment phase with ~$12 million revenue; expected to grow at a high rate over next 2-3 years before profitability improves. - Biologicals have been growing at double-digit rates and expected to continue as a key growth driver over next 5-10 years. - Pharma business showed 54% Y-o-Y growth in H1 FY26; despite biotech funding slowdown, long-term positive outlook with capability building ongoing. - AgChem exports experienced volume-led decline but new products grew 38% Y-o-Y in H1 FY26; 8-10 new molecules planned for commercialization this fiscal. - Domestic business impacted by erratic rainfall and regulatory changes but expected positive trajectory in H2, especially with improved Rabi season outlook. - Overall industry demand expected to normalize and recover by Q4 FY26 with gradual normalization of inventories. - Long-term growth outlook remains intact, focusing on sustainable expansion across Ag Sciences, Pharma CRDMO, Specialty Chemicals, and biologicals.

- Biologicals business is in the investment phase with current revenue around $12 million; high growth expected over next 2-3 years with focus on scaling rather than margins now; profitability to follow as scale improves (Rajnish Sarna, p.18). - Pharma segment is also in investment phase; profitability expected to materialize after 1 year as scale builds (Rajnish Sarna, p.12). - CSM (Custom Synthesis & Manufacturing) segment faces softness in H1 FY26 but recovery expected from Q4 FY26; growth potentially single-digit in second half but full recovery not before H2 2026 or later (Rajnish Sarna & Mayank Singhal, pp.16,7). - Overall, short-term headwinds exist due to climatic and market conditions; however, medium to long-term growth outlook remains positive with expectation to regain momentum in coming years (Mayank Singhal & Sanjay Agarwal, pp.6,4). - EBITDA margins to remain resilient with annual margin guidance maintained despite short-term variability (Mayank Singhal, p.9).

- The current overall order book position stands at approximately $1.25 billion as of Q2 FY26. - The company does not provide order book guidance broken down by specific fiscal years (e.g., FY26 or FY27). - Demand normalization and inventory destocking in the global agrochemical industry are expected to improve order flow visibility from Q4 FY26. - The management anticipates a recovery and positive growth trajectory in the second half of calendar year 2026. - Order book growth is tied to market normalization and customer delivery schedules, with expectations of recovery over the next 2-3 quarters. - No specific order book size forecast for FY27 is provided currently, as it remains too early for clear guidance.